# EDGAR Filing Document

**Accession Number:** 0001682852
**File Stem:** 0001140361-25-041712
**Filing Date:** 2025-11
**Character Count:** 8305
**Document Hash:** 7f7ad90a69ef09c8fa6c37ea4836e4f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-041712.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001140361-25-041712

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moderna, Inc.
- **CENTRAL INDEX KEY:** 0001682852
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813467528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90749
- **FILM NUMBER:** 251474331

**BUSINESS ADDRESS:**
- **STREET 1:** 325 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 6177146500

**MAIL ADDRESS:**
- **STREET 1:** 325 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Moderna Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160822
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moderna, Inc.
- **CENTRAL INDEX KEY:** 0001682852
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813467528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** 325 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 6177146500

**MAIL ADDRESS:**
- **STREET 1:** 325 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Moderna Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160822

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

### SCHEDULE TO

#### TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### (Amendment No.  )

------

### <br>

### Moderna, Inc.

#### (Name of Subject Company (Issuer) and Filing Person (as Offeror))

#### Options to Purchase Common Stock, par value $0.0001 per share

#### (Title of Class of Securities)

#### 60770K107

#### (CUSIP Number of Class of Securities)

#### Stéphane Bancel

#### Chief Executive Officer

#### Moderna, Inc.

#### 325 Binney Street

#### Cambridge, Massachusetts 02142
(617) 714-6500

#### (Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)

------

#### CALCULATION OF FILING FEE

---

| | |
|:---|:---|
| **Transaction Value (1)** | **Amount of Filing Fee (2)** |
| N/A | N/A |

---

\* Pursuant to General Instruction D to Schedule TO, a filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.

☐ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

---

| | |
|:---|:---|
| Amount Previously Paid: Not applicable. | Filing Party: Not applicable. |
| Form or Registration No.: Not applicable. | Date Filed: Not applicable. |

---

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☐ third-party tender offer subject to Rule 14d-1.

☒ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

<br> Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer) <br> ☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

Attached is an email sent to employees of Moderna, Inc., a Delaware corporation (the "Company"), on November 12, 2025 (the "Employee Communications"), related to the proposed stock option exchange program that would allow certain employees who are not executive officers to exchange significantly out-of-the-money or "underwater" stock options, meaning outstanding stock options that have an exercise price that is significantly greater than the market price for the Company's common stock, for the issuance of new stock options that will be exercisable for fewer shares of the Company's common stock, with an exercise price equal to the fair market value of the Company's common stock on the grant date of the new stock options and with new vesting terms (the "Option Exchange Program").

#### The Employee Communications do not constitute an offer to holders of the Company's outstanding stock options to exchange those options.

***The Option Exchange Program has not yet commenced. The Company may decide not to implement the Option Exchange Program. The Company will file a Tender Offer Statement on Schedule TO with the SEC if and when the Option Exchange Program commences. Option holders should read the Tender Offer Statement on Schedule TO and other related materials when those materials become available, because they will contain important information about the Option Exchange Program.***

***The Company's shareholders and option holders will be able to obtain the written materials described above and the other documents filed by the Company with the SEC free of charge from the SEC's website at www.sec.gov or by directing a written request to: Corporate Secretary, at 325 Binney Street, Cambridge, Massachusetts 02142.***

#### Item 12. Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Document** |
| [99.1](ny20056248x6_ex99-1.htm) | Email from the Company's Chief Executive Officer to employees, sent November 12, 2025 |

---

------

## Exhibit 99.1

------

#### Exhibit 99.1

#### Employee Announcement – Program Approved by Shareholders

**To:** All Moderna Employees

**From:** Stéphane Bancel

**Subject:** Stock Option Exchange Program approved

**Date:** Wed, November 12

Dear Team,

The special shareholder meeting was held earlier today, and I am excited to share some good news: our shareholders approved Moderna's one-time stock option exchange program for employees.

#### Why this matters
This is a rare and meaningful program that companies don't typically offer. It gives you the opportunity to exchange eligible underwater stock options for new ones priced at market value, restoring their potential to grow as Moderna grows.

#### What you need to do and by when
Starting tomorrow, November 13 at 9:00 a.m. ET, through December 12, 2025, at 3:59 p.m. ET visit the exchange site (***fidelitymicrosite.com/ModernaExchange***) to make your selections and access on-demand and personalized resources to help you decide what's right for you.

Thank you for everything you do to advance our Mission. This program is another way we are investing in you and the incredible impact you make every day.

Cheers,

Stephane

*This communication is not an offer to exchange any options. The option exchange has not yet commenced, and there can be no assurance that it will be implemented. Moderna will file a Tender Offer Statement on Schedule TO with the SEC if and when the option exchange commences. If Moderna commences the option exchange, we will provide employees who are eligible to participate in the exchange program with written materials explaining the precise terms and timing of the program. The new option grant date and end of the tender offer period is subject to change. You should read these materials carefully when they become available, because they will contain important information about the option exchange. You will also be able to obtain the tender offer statement and other documents filed by Moderna with the SEC free of charge from the SEC's website at* www.sec.gov*.*

------

<br>